INVEGA HAFYERA Paliperidone Palmitate Injection – For Research Use Only

INVEGA HAFYERA Paliperidone Palmitate Injection – For Research Use Only

(1 customer review)

$1.00

INVEGA HAFYERA is a six?month long?acting injectable suspension delivering 350?mg paliperidone palmitate in 1.75?ml per syringe. Approved under HJ20180021 and manufactured by Janssen Pharmaceutica. Ideal for schizophrenia pharmacodynamics, relapse?prevention, and CNS modeling studies. Wholesale & retail supported. For laboratory research use only.?For wholesale prices, other specifications and uses, please consult our staff?

EMI starting from $0.00/month - View Plans
Compare

Description

Paliperidone palmitate is a depot formulation of paliperidone, a dopamine D? and serotonin 5?HT?A receptor antagonist. INVEGA HAFYERA provides sustained plasma exposure with an injection every six months, reducing dosing frequency and enhancing adherence in models of chronic antipsychotic delivery. Widely used in research to simulate long?term CNS drug release, receptor binding kinetics, and relapse prevention studies. Supplied in pre?filled syringes. Strictly for research use only.


Product Specifications

ParameterDetails
Product NameINVEGA HAFYERA Paliperidone Palmitate Injection (3?Month)
SynonymsInvega Hafyera, PP6M, Paliperidone palmitate 6?month, RO?92670
Strength350?mg per 1.75?ml syringe
Packaging1 syringe per box
Dosage FormExtended-release injectable suspension
ManufacturerJanssen Pharmaceutica N.V. (Belgium)
Approval Number???? HJ20180021
Product Code86982023000055
BarcodeNot yet registered
CAS Number199739?10?1
Molecular FormulaC??H??FN?O?·C??H??O?
Molecular Weight~665?g/mol

Mechanism of Action & Research Applications

Paliperidone palmitate is hydrolyzed to paliperidone in vivo, which antagonizes dopamine D? and serotonin 5?HT?A receptors. INVEGA HAFYERA achieves a six?month release profile, making it ideal for modeling chronic antipsychotic therapy, pharmacokinetics of depot formulations, CNS receptor interactions, and relapse prevention in schizophrenia research.


Side Effects (For Reference Only in Research Models)

Based on clinical trial analogs, observed effects may include injection-site reactions, upper respiratory infections, weight gain, headache, extrapyramidal symptoms, increased prolactin, and fatigue. These provide informative safety markers for experimental protocols.


Disclaimer

INVEGA HAFYERA Paliperidone Palmitate Injection is strictly intended for laboratory research use only. Not for human or veterinary therapeutic or diagnostic application.

Additional information

Weight0.8 kg
Dimensions26 × 23 × 26 cm

1 review for INVEGA HAFYERA Paliperidone Palmitate Injection – For Research Use Only

  1. wttonettode

    The package was received, thank you!!!

Add a review

Your email address will not be published. Required fields are marked *

EMI Options

Select at least 2 products
to compare